CADL · Candel Therapeutics, Inc. · Stock research

Current Thesis

The leg that failed in July has re-formed. After the June breakout to $11.36 round-tripped to roughly $9.49 by 2026-07-10, price reclaimed that high in August and closed 2026-08-14 at $11.72, within 0.7% of the $11.80 52-week high, +33.6% over three months. The proximate news is not clinical: the 2026-08-13 Q2 release reaffirmed a Q4 2026 BLA submission for aglatimagene besadenovec in localized intermediate- to high-risk prostate cancer, put cash at $201.6M as of 2026-06-30 against $119.7M at 2025-12-31, and guided runway into Q1 2028 — funded past the filing. What an investor is buying is the pre-filing re-rating of a first-in-class viral immunotherapy toward an approval decision, with AURORA (post-ICI metastatic non-squamous NSCLC, first site activated June 2026, ~150 planned sites, overall-survival primary) as the second, larger pivotal shot. What they are not buying is a dated event: nothing company-confirmed sits inside the next 30 days, ASTRO runs 2026-09-26 to 09-30, and the BLA itself has no day-level date. RSI(14) at 76.5 into that gap is the awkward part of the entry, not the thesis.

The narrative is accelerating, dated by the August reclaim of the June $11.36 high and the 2026-08-14 close at a fresh 52-week-high area, with three headlines in two sessions (Q2 print 8/13, HC Wainwright Buy/$23 reiteration 8/13, B. of A. Neutral with target raised to $12 on 8/14). The label is fragile: the flow is analyst- and balance-sheet-driven rather than data-driven, so it flips toward maturing if ASTRO passes without an expansion in participation.

Bullish and bearish views on Candel Therapeutics, Inc.

The model's bull view on Candel Therapeutics, Inc. (CADL), in brief: BLA timing held at the print. 2026-08-13 release: BLA submission for aglatimagene besadenovec planned Q4 2026 — no slip disclosed versus the guidance carried since Q1. Balance sheet strengthened into the filing. Cash $201.6M at 2026-06-30 versus $119.7M at 2025-12-31; runway… The bear view: The print missed by a wide margin. Q2 2026 EPS $(0.52) against a $(0.23) consensus; net loss $38.9M versus $4.8M a year earlier. Most of the gap is non-cash — net other expense of $12.2M, primarily the change in fair value of warrant liabilities — but operating spend also… Both cases follow in full.

Bull Case

• BLA timing held at the print. 2026-08-13 release: BLA submission for aglatimagene besadenovec planned Q4 2026 — no slip disclosed versus the guidance carried since Q1.
• Balance sheet strengthened into the filing. Cash $201.6M at 2026-06-30 versus $119.7M at 2025-12-31; runway guided into Q1 2028, i.e. past a Q4 2026 submission and an FDA acceptance decision.
• Structure repaired. The June high of $11.36 that failed in July was taken back in August; the 2026-08-14 close of $11.72 sits 0.7% under the $11.80 52-week high. Three-month return +33.6%.
• Second pivotal, far larger indication. AURORA Phase 3 first site activated June 2026, enrolment ongoing across ~150 global sites, overall survival as primary endpoint.
• Efficacy is peer-reviewed. Lancet Oncology, 2026-06-02: disease-free-survival HR 0.70 (95% CI 0.52–0.94, p=0.016), n=745, plus AUA extended follow-up presented 2026-05-15.
• Two more company-guided readouts before year-end. Extended biomarker data at ASTRO in Q3 2026 and potential long-term survival data from the linoserpaturev arm C in Q4 2026, both per the 2026-08-13 release.
• Bull-side targets sit far above the tape. HC Wainwright Buy $23 reiterated 2026-08-13; Stifel Buy $22 (2026-07-13); Canaccord $25.

Bear Case

• The print missed by a wide margin. Q2 2026 EPS $(0.52) against a $(0.23) consensus; net loss $38.9M versus $4.8M a year earlier. Most of the gap is non-cash — net other expense of $12.2M, primarily the change in fair value of warrant liabilities — but operating spend also stepped up hard: R&D $19.8M versus $7.0M in Q2 2025, G&A $6.9M versus $4.2M.
• Runway language narrowed. The Q1 release guided "into 2028"; the 2026-08-13 release specifies "into Q1 2028". Same balance sheet, tighter wording.
• The marginal new coverage is capped at the tape. B. of A. raised its target to $12 on 2026-08-14 while maintaining Neutral — roughly the last close. The wide bull targets are reiterations, not new money entering coverage.
• This name has failed a new high once already this cycle. June's $11.36 print retraced to about $9.49 by 2026-07-10 on unremarkable volume. RSI(14) 76.5 at 2026-08-14 is the same condition that preceded that failure.
• No dated binary for 41 days. ASTRO 2026-09-26 to 09-30 is the nearest scheduled venue; the BLA is a quarter-level guide.
• Covenant reflexivity below. The Trinity term loan carries a market-cap covenant near $550M; a breach pledges cash against the $50M facility — a liquidity constraint driven by the share price itself.
• Governance overhang unresolved. A legacy data-integrity matter tied to former leadership remains a BLA-acceptance risk independent of the efficacy dataset.

Setup & Price Structure

Reference close 2026-08-14: $11.72. 52-week high $11.80, so price is 0.7% below it. Three-month return +33.6%; RSI(14) 76.5.

Levels that matter: $11.36 is the June high and now the breakout shelf the August advance is standing on; $9.27 is the old 52-week high whose loss in July defined the failed leg and which returns price to the dead April–June range; $11.80 is the overhead line the tape has not closed above.

Positioning and crowding observables, stated as observables: RSI(14) at 76.5 with price inside 1% of the 52-week high; a fresh sell-side action on each of the two sessions around the print, one of which (B. of A., 2026-08-14) carries a Neutral rating and a $12 target barely above the last close; weighted-average basic shares of 74.1M in Q2 2026 against the ~73.3M count used in earlier coverage; warrant liabilities carried at fair value, marked at $12.2M of net other expense in the quarter. Cash rose quarter-on-quarter — $201.6M at 2026-06-30 versus the $195M reported at 2026-03-31 — despite R&D of $19.8M and G&A of $6.9M in the period. INFERRED, not disclosed in the results release reviewed: that increase implies a financing inflow during Q2, most plausibly warrant exercises, which would add shares into strength. No insider transactions surfaced in the current filing window; the CCO option strike of $10.03 disclosed on the 2026-07-06 effective date is now in the money.

Catalyst Calendar (next 30 days)

• None company-confirmed inside the window through ~2026-09-15. This is the state of the calendar, not an oversight in it.
• 2026-09-26 to 2026-09-30 — ASTRO 2026 Annual Meeting, Boston. The 2026-08-13 release guided extended biomarker data at ASTRO in Q3 2026; the abstract is the only scheduled venue before the BLA quarter.
• ~2026-11-12 (est., unconfirmed) — Q3 2026 results. The checkpoint on whether the Q4 2026 BLA is still on schedule and on the Q2 share-count change.
• Q4 2026 (company-guided, no day-level date) — BLA submission for aglatimagene besadenovec.
• Q4 2026 (company-guided) — potential long-term survival data from the linoserpaturev arm C.

What Would Change Our Mind

The structural break is the loss of the shelf the August advance was built on. The June high at $11.36 failed once already; giving it back a second time would mean the reclaim was a liquidity event around the print rather than a trend. A weekly close below $11.36 is the gradeable version of that break, and a subsequent daily close under $9.27 returns price to the April–June range where the name went nowhere for two months.

Three non-price conditions would do the same work. First, ASTRO passing (2026-09-26 to 09-30) with the biomarker data presented and no expansion in volume or coverage would date the flip from accelerating to maturing. Second, any language at the Q3 print moving the BLA out of Q4 2026 removes the only hard binary on the board. Third, a Q3 share count materially above the 74.1M weighted-average basic of Q2, or a fresh shelf takedown, would confirm that the balance-sheet improvement is being funded by issuance into the rally rather than by the story working.

Correlation Notes

• Small-cap, pre-revenue, catalyst-driven biotech: the name trades with XBI-type risk appetite and with the rate path between dated events, and decorrelates around its own data.
• Warrant liabilities create an inverse mechanic between the share price and reported GAAP EPS — a rising stock raises the liability mark and widens the reported loss. Q2 2026's $12.2M net other expense is the observable version of that, and it explains most of the $(0.52) versus $(0.23) gap without telling a reader anything about operating burn.
• The Trinity market-cap covenant near $550M makes the downside path reflexive rather than linear: weakness that approaches it converts into a cash-pledge event, which is a different regime from an ordinary drawdown.
• The prostate BLA and AURORA share one asset. A safety or manufacturing problem in aglatimagene besadenovec is not diversified across the two programmes; only the glioma asset, now carrying the INN linoserpaturev, sits outside that single point of failure.